Every material Form 8-K Cabaletta Bio, Inc. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cabaletta Bio released new Phase 1/2 clinical data on its investigational cell therapy rese-cel, presented at the ACR Convergence 2026 meeting, covering dermatomyositis, lupus nephritis, and systemic sclerosis patients followed up to one year. The company reported that 100% (6/6) of dermatomyositis patients maintained immunomodulator-free responses through one year, and it reiterated plans for registrational topline results in the second half of 2027 and a planned BLA submission in the first quarter of 2028. The sample sizes are small, and the filing does not report any financial figures.
100% (6/6) of dermatomyositis patients maintained immunomodulator-free, moderate-to-major TIS responses through one year
71% (5/7) of systemic sclerosis patients achieved rCRISS-50 at one year; five patients with interstitial lung disease showed 9% mean FVC improvement
Grade 2 cytokine release syndrome was reported in 6% (4/71) of 71 patients; no IEC-HS was reported
Registrational topline results expected in 2H 2027; planned BLA submission in myositis in 1Q 2028
Cabaletta Bio reported third-quarter 2026 results, with a net loss of $53.1 million, up from $44.9 million a year earlier, though the per-share loss narrowed to $0.28 from $0.44. The company said cash of $299.4 million, including about $115.0 million from warrant exercises, extends its operating runway into the first quarter of 2028.
Q3 2026 net loss was $53.1 million, or $0.28 per share, versus $44.9 million, or $0.44 per share, in Q3 2025.
Research and development expenses rose to $47.1 million from $39.8 million; general and administrative expenses rose to $7.6 million from $6.8 million.
Cash and cash equivalents were $299.4 million at September 30, 2026, including about $115.0 million from warrant exercises before their September 12, 2026 expiration.
RESET-Myositis registrational topline results are expected in the second half of 2027, with a BLA submission planned for the first quarter of 2028.
Cabaletta Bio said holders exercised warrants from its June 2025 underwritten public offering, bringing aggregate gross proceeds to approximately $128.2 million through the September 12, 2026 expiration date. Most of that total, 46,011,900 warrants for approximately $115.0 million, was exercised from July 1, 2026 through expiration. For shareholders, the exercises add cash to the company at a fixed exercise price of $2.50 per share.
Warrants issued in the June 2025 offering: 53,090,190, each with an exercise price of $2.50 per whole share
From July 1, 2026 through September 12, 2026: 46,011,900 warrants exercised for approximately $115.0 million in gross proceeds
Total gross proceeds from exercises through the expiration date: approximately $128.2 million, including $13.2 million from 5,275,100 warrants exercised through June 30, 2026
Cabaletta Bio reported a second-quarter 2026 net loss of $51.0 million, up from $45.1 million a year earlier, as research and development expenses rose to $44.4 million from $37.6 million. Cash, cash equivalents and short-term investments rose to $225.1 million at June 30, 2026, helped by a May 2026 registered direct offering, and the company expects this to fund operations into mid-2027.
Net loss was $51.0 million for the quarter ended June 30, 2026, versus $45.1 million for the same period in 2025.
Net loss per share was $0.34, compared with $0.73 a year earlier.
R&D expenses were $44.4 million versus $37.6 million; G&A expenses were $7.6 million versus $8.3 million.
Cash and short-term investments were $225.1 million, up from $133.6 million at December 31, 2025; the company expects to fund operations into mid-2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cabaletta Bio, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →